<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03137771</url>
  </required_header>
  <id_info>
    <org_study_id>NRG-LU002</org_study_id>
    <secondary_id>NCI-2016-00849</secondary_id>
    <secondary_id>NRG-LU002</secondary_id>
    <secondary_id>NRG-LU002</secondary_id>
    <secondary_id>U10CA180868</secondary_id>
    <nct_id>NCT03137771</nct_id>
  </id_info>
  <brief_title>Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer</brief_title>
  <official_title>Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NRG Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II/III trial studies how well giving maintenance chemotherapy with or
      without stereotactic body radiation therapy works in treating patients with stage IV
      non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel,
      pemetrexed disodium, and gemcitabine work in different ways to stop the growth of tumor
      cells, either by killing the cells, by stopping them from dividing, or by stopping them from
      spreading. Stereotactic body radiation therapy is a specialized radiation therapy that sends
      x-rays directly to the tumor using smaller doses over several days and may cause less damage
      to normal tissue. Giving maintenance chemotherapy and stereotactic body radiation therapy
      together may work better than maintenance chemotherapy alone in treating patients with stage
      IV non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      Phase II

      To evaluate the impact of adding stereotactic body radiation therapy (SBRT) to maintenance
      systemic therapy versus maintenance systemic therapy alone on progression-free survival for
      patients with metastatic non-small cell lung cancer (NSCLC) with no evidence of progression
      and limited metastatic sites after first-line systemic therapy.

      Phase III

      To evaluate the impact of adding SBRT to maintenance systemic therapy versus maintenance
      systemic therapy alone on overall survival for patients with metastatic NSCLC with no
      evidence of progression and limited metastatic sites after first-line systemic therapy.

      SECONDARY OBJECTIVES:

      I. To evaluate the impact of adding SBRT to maintenance systemic therapy versus maintenance
      systemic therapy alone on in-field local failure.

      II. To evaluate the impact of adding SBRT to maintenance systemic therapy versus maintenance
      systemic therapy alone on primary failure.

      III. To evaluate the impact of adding SBRT to maintenance systemic therapy versus maintenance
      systemic therapy alone on out-of-field disease progression.

      IV. To evaluate the impact of adding SBRT to maintenance systemic therapy versus maintenance
      systemic therapy alone on toxicity.

      V. To evaluate the impact of adding SBRT to maintenance systemic therapy versus maintenance
      systemic therapy alone on duration of maintenance systemic chemotherapy usage.

      VI. To evaluate the effect of adding SBRT to systemic therapy in limited stage IV NSCLC on
      Quality of Life (QOL)

      OUTLINE: Patients are randomized into 1 of 2 arms.

      ARM 1 (CHEMOTHERAPY ALONE): Patients may receive docetaxel intravenously (IV) over 60 minutes
      on Day 1, or gemcitabine IV over 30 minutes on Days 1 and 8. Patients with non-squamous
      non-small cell lung cancer may receive pemetrexed disodium IV over 10 minutes on Day 1.
      Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

      ARM 2 (SBRT AND CHEMOTHERAPY): Patients undergo SBRT to all sites of metastases (â‰¤3 discrete
      sites) plus irradiation of the primary site (SBRT or hypofractionated RT) followed by
      chemotherapy as in Arm 1.

      After completion of study treatment, patients are followed up every 3 months for 2 years,
      every 6 months for 3 years, then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2017</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase II - Progression-Free Survival (PFS)</measure>
    <time_frame>From the time of randomization to date any documented progression or death due to any cause, whichever occurs first. Assessed for up to 3 years.</time_frame>
    <description>Progression-Free Survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase III - Overall Survival (OS)</measure>
    <time_frame>From the time of randomization to date of death due to any cause. Assessed up to 3 years.</time_frame>
    <description>Overall Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to In-Field Failure</measure>
    <time_frame>Time from randomization to progression within the irradiated field at any time, assessed for up to 3 years</time_frame>
    <description>The time it takes for disease progression to occur within the radiation treatment field of disease will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Out-of-Field Failure</measure>
    <time_frame>Time from randomization to out-field disease progression, assessed for up to 3 years</time_frame>
    <description>The time is takes for disease progression to occur outside of the radiation treatment field of disease will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events graded per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be reported with the frequency and severity (e.g., type, grade, and attribution) by arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Maintenance Chemotherapy Usage</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be performed on an intent to treat basis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Recurrent Non-Small Cell Lung Carcinoma</condition>
  <condition>Stage IV Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1 (maintenance chemotherapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients may receive docetaxel IV over 60 minutes on Day 1, or gemcitabine IV over 30 minutes on Days 1 and 8. Patients with non-squamous non-small cell lung cancer may receive pemetrexed disodium IV over 10 minutes on Day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (SBRT + maintenance chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo SBRT over 2-4 weeks. If SBRT cannot be used to treat primary disease sites, patients also undergo IMRT or 3D-CRT over 3-5 weeks. Within 2 weeks after completion of radiation therapy, patients receive chemotherapy as in Arm 1 (docetaxel IV over 60 minutes on Day 1, or gemcitabine IV over 30 minutes on Days 1 and 8. Patients with non-squamous non-small cell lung cancer may receive pemetrexed disodium IV over 10 minutes on Day 1).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-Dimensional Conformal Radiation Therapy (3D-CRT)</intervention_name>
    <description>Undergo 3DCRT</description>
    <arm_group_label>Arm 2 (SBRT + maintenance chemotherapy)</arm_group_label>
    <other_name>3-dimensional conformal radiation therapy</other_name>
    <other_name>3-dimensional radiation therapy</other_name>
    <other_name>3D CONFORMAL RADIATION THERAPY</other_name>
    <other_name>3D CRT</other_name>
    <other_name>3D-CRT</other_name>
    <other_name>Conformal Therapy</other_name>
    <other_name>Radiation Conformal Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm 1 (maintenance chemotherapy)</arm_group_label>
    <arm_group_label>Arm 2 (SBRT + maintenance chemotherapy)</arm_group_label>
    <other_name>Docecad</other_name>
    <other_name>RP56976</other_name>
    <other_name>Taxotere</other_name>
    <other_name>Taxotere Injection Concentrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm 1 (maintenance chemotherapy)</arm_group_label>
    <arm_group_label>Arm 2 (SBRT + maintenance chemotherapy)</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy (IMRT)</intervention_name>
    <description>Undergo IMRT</description>
    <arm_group_label>Arm 2 (SBRT + maintenance chemotherapy)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>INTENSITY-MODULATED RADIATION THERAPY</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed Disodium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm 1 (maintenance chemotherapy)</arm_group_label>
    <arm_group_label>Arm 2 (SBRT + maintenance chemotherapy)</arm_group_label>
    <other_name>Alimta</other_name>
    <other_name>LY231514</other_name>
    <other_name>N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy (SBRT)</intervention_name>
    <description>Undergo SBRT</description>
    <arm_group_label>Arm 2 (SBRT + maintenance chemotherapy)</arm_group_label>
    <other_name>SBRT</other_name>
    <other_name>stereotactic body radiation therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have the psychological ability and general health that permits
             completion of the study requirements and required follow up

          -  Women of childbearing potential and men who are sexually active should be willing and
             able to use medically acceptable forms of contraception during the trial

          -  Pathologically proven diagnosis of NSCLC, with metastases (stage IV disease) present
             prior to registration; this includes patients newly diagnosed with metastatic disease
             or those initially diagnosed and treated for stage I-III NSCLC who ultimately develop
             metastases

          -  Appropriate stage for study entry based on the following diagnostic workup:

               -  History/physical examination within 30 days prior to registration

               -  Imaging proof of limited metastatic disease and response to therapy/stable
                  disease, by at least CT chest through the adrenals or PET/CT within 30 days prior
                  to registration

          -  Zubrod performance status 0, 1, or 2 within 30 days prior to registration

          -  Aspartate transaminase (AST) and alanine transaminase (ALT) â‰¤ 2.5 Ã— upper limit of
             normal (ULN) or â‰¤ 5 Ã— ULN with metastatic liver disease

          -  Total bilirubin â‰¤ 1.5 Ã— ULN

          -  Absolute neutrophil count (ANC) â‰¥ 500 cells/mm^3

          -  Creatinine clearance â‰¥ 45 mL/min/1.73 m^2 for patients with creatinine levels above
             institutional normal

          -  Platelets â‰¥ 50,000 cells/mm^3

          -  Negative serum pregnancy test within one week prior to registration for females of
             childbearing potential

          -  Patients must have received first-line/induction chemotherapy (4 cycles) and achieved
             stable disease or a partial response

          -  Prior systemic chemotherapy as part of concurrent treatment approach for previously
             diagnosed stage III NSCLC, as adjuvant therapy for previously resected NSCLC, or for
             other previous cancers is permitted

          -  Prior radiotherapy for patients with brain metastases prior to enrollment is
             acceptable

          -  Patients must have measurable disease at baseline and 3 or fewer discrete,
             extracranial metastatic disease sites that are technically amenable to SBRT

          -  For de novo stage IV NSCLC patients (patients with metastatic disease at first
             presentation), primary disease must be treatable with local therapy in the form of
             SBRT or hypofractionated radiation; if the primary disease is found in the peripheral
             or central lung parenchyma without nodal disease for instance, SBRT may be employed;
             if primary disease is more advanced with involvement of the mediastinum (T4 tumor,
             N1-N3 disease, etc.), these volumes should be technically treatable with
             hypofractionated radiation

          -  If primary disease in the thoracic cavity was previously treated with local therapy in
             the form of surgery, any local/regional disease recurrence should be technically
             treatable with SBRT or hypofractionated radiation after induction systemic therapy

          -  Patients must be registered within 35 days of administration of the last dose of
             first-line/induction systemic therapy

          -  The patient or a legally authorized representative must provide study-specific
             informed consent prior to study entry

          -  Patients with brain metastases are eligible if these lesions have been previously
             treated and the patients have no clinical or radiographic evidence of progression
             prior to enrollment

        Exclusion Criteria:

          -  Clinical or radiologic evidence of untreated and/or progressive brain metastases

          -  Cutaneous metastasis of NSCLC

          -  Metastatic disease invading the esophagus, stomach, intestines, or mesenteric lymph
             nodes

          -  Prior invasive malignancy (except non-melanomatous skin cancer, low or intermediate
             risk prostate cancer, or in situ carcinoma of breast, oral cavity, skin, or cervix)
             unless disease free for a minimum of one year

          -  Metastases located within 3 cm of previously irradiated (&lt; 3Gy per fraction)
             structures if:

               -  Spinal cord previously irradiated to &gt; 40 Gy

               -  Brachial plexus previously irradiated to &gt; 50 Gy

               -  Small intestine, large intestine, or stomach previously irradiated to &gt; 45 Gy

               -  Brainstem previously irradiated to &gt; 50 Gy

               -  Lung previously irradiated with prior V20 Gy &gt; 35%

          -  Patients receiving targeted therapy (non-cytotoxic systemic therapy) for NSCLC in the
             first-line setting

          -  If a patient has progressed in previous areas of primary disease that received
             definitive doses of radiation, these patients would require re-irradiation in previous
             high dose anatomic areas and are not eligible for this study

          -  Patients with malignant pleural effusions that do not resolve after first-line
             systemic therapy; patients with pleural effusions that have become too small for
             thoracentesis at the time of registration would be permitted on study, indicating a
             significant response to first-line chemotherapy

          -  Patients with more than 3 discrete locations of extra-cranial metastatic disease after
             first-line systemic therapy requiring more than 3 SBRT plans to cover these distinct
             metastatic disease entities

          -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time of
             registration

          -  Patients who are pregnant or nursing

          -  Participation in any investigational drug study (excluding non-oncology and/or symptom
             management studies) within 4 weeks prior to registration

          -  Known human immunodeficiency virus (HIV) positive with cluster of differentiation 4
             (CD4) count &lt; 200 cells/microliter; note that patients who are HIV positive are
             eligible, provided they are under treatment with highly active antiretroviral therapy
             (HAART) and have a CD4 count â‰¥ 200 cells/microliter within 30 days prior to
             registration; note also that HIV testing is not required for eligibility for this
             protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Puneeth Iyengar</last_name>
    <role>Principal Investigator</role>
    <affiliation>NRG Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Cancer Center-Orange Grove Campus</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles C. Hsu</last_name>
      <phone>520-694-8900</phone>
    </contact>
    <investigator>
      <last_name>Charles C. Hsu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Arizona Medical Center-University Campus</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles C. Hsu</last_name>
      <phone>520-626-9008</phone>
    </contact>
    <investigator>
      <last_name>Charles C. Hsu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alta Bates Summit Medical Center-Herrick Campus</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher U. Jones</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher U. Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sagus Sampath</last_name>
      <phone>800-826-4673</phone>
      <email>becomingapatient@coh.org</email>
    </contact>
    <investigator>
      <last_name>Sagus Sampath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James J. Urbanic</last_name>
      <phone>858-822-5354</phone>
      <email>cancercto@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>James J. Urbanic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Los Angeles County-USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason C. Ye</last_name>
      <phone>323-865-0451</phone>
    </contact>
    <investigator>
      <last_name>Jason C. Ye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason C. Ye</last_name>
      <phone>323-865-0451</phone>
    </contact>
    <investigator>
      <last_name>Jason C. Ye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Hospital - Orange</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert B. Ash</last_name>
      <phone>714-734-6220</phone>
    </contact>
    <investigator>
      <last_name>Robert B. Ash</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Permanente Medical Group-Roseville Radiation Oncology</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95678</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha A. Seaward</last_name>
      <phone>510-891-3400</phone>
    </contact>
    <investigator>
      <last_name>Samantha A. Seaward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Medical Center Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher U. Jones</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher U. Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan E. Daly</last_name>
      <phone>916-734-3089</phone>
    </contact>
    <investigator>
      <last_name>Megan E. Daly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Helena Hospital</name>
      <address>
        <city>Saint Helena</city>
        <state>California</state>
        <zip>94574</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory B. Smith</last_name>
      <phone>707-967-3698</phone>
    </contact>
    <investigator>
      <last_name>Gregory B. Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope South Pasadena</name>
      <address>
        <city>South Pasadena</city>
        <state>California</state>
        <zip>91030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sagus Sampath</last_name>
      <phone>800-826-4673</phone>
      <email>becomingapatient@coh.org</email>
    </contact>
    <investigator>
      <last_name>Sagus Sampath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Cancer Treatment Center</name>
      <address>
        <city>South San Francisco</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha A. Seaward</last_name>
      <phone>510-891-3400</phone>
    </contact>
    <investigator>
      <last_name>Samantha A. Seaward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gene Upshaw Memorial Tahoe Forest Cancer Center</name>
      <address>
        <city>Truckee</city>
        <state>California</state>
        <zip>96161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan E. Daly</last_name>
      <phone>530-582-6450</phone>
    </contact>
    <investigator>
      <last_name>Megan E. Daly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penrose-Saint Francis Healthcare</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet S. Copur</last_name>
      <phone>308-398-6518</phone>
      <email>clinicaltrials@sfmc-gi.org</email>
    </contact>
    <investigator>
      <last_name>Mehmet S. Copur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCHealth Memorial Hospital Central</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony D. Elias</last_name>
      <phone>719-365-2406</phone>
    </contact>
    <investigator>
      <last_name>Anthony D. Elias</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poudre Valley Hospital</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80524</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony D. Elias</last_name>
      <phone>970-297-6150</phone>
    </contact>
    <investigator>
      <last_name>Anthony D. Elias</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy H. Decker</last_name>
      <phone>203-785-5702</phone>
      <email>canceranswers@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Roy H. Decker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen F Graham Cancer Center</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory A. Masters</last_name>
      <phone>302-623-4450</phone>
      <email>KDempsey@christianacare.org</email>
    </contact>
    <investigator>
      <last_name>Gregory A. Masters</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Science Center - Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anamaria R. Yeung</last_name>
      <phone>412-339-5294</phone>
      <email>Roster@nrgoncology.org</email>
    </contact>
    <investigator>
      <last_name>Anamaria R. Yeung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tallahassee Memorial HealthCare</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen B. Russell</last_name>
      <phone>850-431-5566</phone>
      <email>Theresa.Shannon@tmh.org</email>
    </contact>
    <investigator>
      <last_name>Karen B. Russell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic-Weston</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory M. M. Videtic</last_name>
      <phone>954-659-5705</phone>
    </contact>
    <investigator>
      <last_name>Gregory M. M. Videtic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grady Health System</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin A. Higgins</last_name>
      <phone>404-489-9164</phone>
    </contact>
    <investigator>
      <last_name>Kristin A. Higgins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin A. Higgins</last_name>
      <phone>888-946-7447</phone>
    </contact>
    <investigator>
      <last_name>Kristin A. Higgins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin A. Higgins</last_name>
      <phone>404-778-1868</phone>
    </contact>
    <investigator>
      <last_name>Kristin A. Higgins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Saint Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin A. Higgins</last_name>
      <phone>412-339-5294</phone>
      <email>Roster@nrgoncology.org</email>
    </contact>
    <investigator>
      <last_name>Kristin A. Higgins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lewis Cancer and Research Pavilion at Saint Joseph's/Candler</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard A. Zaren</last_name>
      <phone>412-339-5294</phone>
      <email>Roster@nrgoncology.org</email>
    </contact>
    <investigator>
      <last_name>Howard A. Zaren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth N. Sumida</last_name>
      <phone>412-339-5294</phone>
      <email>Roster@nrgoncology.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth N. Sumida</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cancer Center of Hawaii-Liliha</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth N. Sumida</last_name>
      <phone>808-547-6881</phone>
    </contact>
    <investigator>
      <last_name>Kenneth N. Sumida</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy J. Kruser</last_name>
      <phone>312-695-1301</phone>
      <email>cancer@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy J. Kruser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-4740</phone>
      <email>rhamrick@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OSF Saint Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>309-243-3605</phone>
      <email>andersonj@illinoiscancercare.com</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-788-3528</phone>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel H. Barnett</last_name>
      <phone>800-446-5532</phone>
      <email>Research@carle.com</email>
    </contact>
    <investigator>
      <last_name>Daniel H. Barnett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkview Hospital Randallia</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian K. Chang</last_name>
      <phone>260-373-8888</phone>
      <email>parkviewresearch@parkview.com</email>
    </contact>
    <investigator>
      <last_name>Brian K. Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franciscan Health Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael S. Eaton</last_name>
      <phone>317-528-7060</phone>
    </contact>
    <investigator>
      <last_name>Michael S. Eaton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iowa Methodist Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert J. Behrens</last_name>
      <phone>515-241-6727</phone>
    </contact>
    <investigator>
      <last_name>Robert J. Behrens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fen Wang</last_name>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Fen Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center-Overland Park</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fen Wang</last_name>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Fen Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Via Christi Regional Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavan S. Reddy</last_name>
      <phone>800-362-0070</phone>
      <email>Keisha.humphries@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Pavan S. Reddy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pranshu Mohindra</last_name>
      <phone>800-888-8823</phone>
    </contact>
    <investigator>
      <last_name>Pranshu Mohindra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Maryland Radiation Oncology in Howard County</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pranshu Mohindra</last_name>
      <phone>443-546-1300</phone>
    </contact>
    <investigator>
      <last_name>Pranshu Mohindra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tate Cancer Center</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pranshu Mohindra</last_name>
      <phone>410-553-8100</phone>
    </contact>
    <investigator>
      <last_name>Pranshu Mohindra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peninsula Regional Medical Center</name>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <zip>21801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John R. Mansueti</last_name>
      <phone>866-922-6237</phone>
    </contact>
    <investigator>
      <last_name>John R. Mansueti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberley S. Mak</last_name>
      <phone>617-638-8265</phone>
    </contact>
    <investigator>
      <last_name>Kimberley S. Mak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital and Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul J. Hesketh</last_name>
      <phone>781-744-8027</phone>
    </contact>
    <investigator>
      <last_name>Paul J. Hesketh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Macomb Hospital-Clinton Township</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor M. Walker</last_name>
      <phone>313-916-1784</phone>
    </contact>
    <investigator>
      <last_name>Eleanor M. Walker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor M. Walker</last_name>
      <phone>313-916-1784</phone>
    </contact>
    <investigator>
      <last_name>Eleanor M. Walker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen J. Yost</last_name>
      <phone>616-391-1230</phone>
      <email>crcwm-regulatory@crcwm.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen J. Yost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Clinic North-Bemidgi</name>
      <address>
        <city>Bemidji</city>
        <state>Minnesota</state>
        <zip>56601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preston D. Steen</last_name>
      <phone>218-333-5000</phone>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital of Duluth</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven R. Bonin</last_name>
      <phone>412-339-5294</phone>
      <email>Roster@nrgoncology.org</email>
    </contact>
    <investigator>
      <last_name>Steven R. Bonin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clifford G. Robinson</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Clifford G. Robinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>314-996-5569</phone>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>314-251-6770</phone>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kalispell Regional Medical Center</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello</last_name>
      <phone>406-969-6060</phone>
      <email>mccinfo@mtcancer.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin T. Marchello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alegent Health Bergan Mercy Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet S. Copur</last_name>
      <phone>308-398-6518</phone>
      <email>clinicaltrials@sfmc-gi.org</email>
    </contact>
    <investigator>
      <last_name>Mehmet S. Copur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renown Regional Medical Center</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John A. Ellerton</last_name>
      <phone>702-384-0013</phone>
      <email>research@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>John A. Ellerton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wentworth-Douglass Hospital</name>
      <address>
        <city>Dover</city>
        <state>New Hampshire</state>
        <zip>03820</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arul Mahadevan</last_name>
      <phone>603-740-2150</phone>
    </contact>
    <investigator>
      <last_name>Arul Mahadevan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virtua Memorial</name>
      <address>
        <city>Mount Holly</city>
        <state>New Jersey</state>
        <zip>08060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lemuel S. Ariaratnam</last_name>
      <phone>609-914-6762</phone>
    </contact>
    <investigator>
      <last_name>Lemuel S. Ariaratnam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virtua Voorhees</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lemuel S. Ariaratnam</last_name>
      <phone>856-247-7395</phone>
    </contact>
    <investigator>
      <last_name>Lemuel S. Ariaratnam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lovelace Medical Center-Saint Joseph Square</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory N. Gan</last_name>
      <phone>505-272-0530</phone>
      <email>AYost@nmcca.org</email>
    </contact>
    <investigator>
      <last_name>Gregory N. Gan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory N. Gan</last_name>
      <phone>505-925-0366</phone>
      <email>LByatt@nmcca.org</email>
    </contact>
    <investigator>
      <last_name>Gregory N. Gan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lovelace Radiation Oncology</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory N. Gan</last_name>
      <phone>505-272-0530</phone>
      <email>AYost@nmcca.org</email>
    </contact>
    <investigator>
      <last_name>Gregory N. Gan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nitin Ohri</last_name>
      <phone>718-904-2730</phone>
      <email>aecc@aecom.yu.edu</email>
    </contact>
    <investigator>
      <last_name>Nitin Ohri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth E. Rosenzweig</last_name>
      <phone>212-824-7309</phone>
      <email>CCTO@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth E. Rosenzweig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuhchyau Chen</last_name>
      <phone>585-275-5830</phone>
    </contact>
    <investigator>
      <last_name>Yuhchyau Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig E. Grossman</last_name>
      <phone>800-862-2215</phone>
    </contact>
    <investigator>
      <last_name>Craig E. Grossman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dickstein Cancer Treatment Center</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey M. Vainshtein</last_name>
      <phone>914-849-7582</phone>
      <email>mcortese@wphospital.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey M. Vainshtein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas E. Stinchcombe</last_name>
      <phone>888-275-3853</phone>
    </contact>
    <investigator>
      <last_name>Thomas E. Stinchcombe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Atlantic Radiation Oncology</name>
      <address>
        <city>Supply</city>
        <state>North Carolina</state>
        <zip>28462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael A. Papagikos</last_name>
      <phone>910-754-4716</phone>
    </contact>
    <investigator>
      <last_name>Michael A. Papagikos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Hanover Regional Medical Center/Zimmer Cancer Center</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael A. Papagikos</last_name>
      <phone>910-342-3000</phone>
    </contact>
    <investigator>
      <last_name>Michael A. Papagikos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHRMC Radiation Oncology - 16th Street</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael A. Papagikos</last_name>
      <phone>910-251-1839</phone>
    </contact>
    <investigator>
      <last_name>Michael A. Papagikos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Bismarck Medical Center</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preston D. Steen</last_name>
      <phone>701-323-5760</phone>
      <email>tamara.fischer@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roger Maris Cancer Center</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preston D. Steen</last_name>
      <phone>701-234-6161</phone>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Akron General</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchel L. Fromm</last_name>
      <phone>330-344-6348</phone>
    </contact>
    <investigator>
      <last_name>Mitchel L. Fromm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Machtay</last_name>
      <phone>800-641-2422</phone>
    </contact>
    <investigator>
      <last_name>Mitchell Machtay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center/Fairview Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory M. M. Videtic</last_name>
      <phone>216-476-9362</phone>
    </contact>
    <investigator>
      <last_name>Gregory M. M. Videtic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory M. M. Videtic</last_name>
      <phone>866-223-8100</phone>
    </contact>
    <investigator>
      <last_name>Gregory M. M. Videtic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose G. Bazan</last_name>
      <phone>800-293-5066</phone>
      <email>Jamesline@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Jose G. Bazan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Mark H Zangmeister Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy D. Moore</last_name>
      <phone>614-488-2118</phone>
      <email>sheree@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center Mansfield</name>
      <address>
        <city>Mansfield</city>
        <state>Ohio</state>
        <zip>44906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory M. M. Videtic</last_name>
      <phone>412-339-5294</phone>
      <email>Roster@nrgoncology.org</email>
    </contact>
    <investigator>
      <last_name>Gregory M. M. Videtic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hillcrest Hospital Cancer Center</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory M. M. Videtic</last_name>
      <phone>440-312-4293</phone>
      <email>hugneyc@cchseast.org</email>
    </contact>
    <investigator>
      <last_name>Gregory M. M. Videtic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Coast Cancer Care</name>
      <address>
        <city>Sandusky</city>
        <state>Ohio</state>
        <zip>44870</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory M. M. Videtic</last_name>
      <phone>412-339-5294</phone>
      <email>Roster@nrgoncology.org</email>
    </contact>
    <investigator>
      <last_name>Gregory M. M. Videtic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. S. Thompson</last_name>
      <phone>405-271-8777</phone>
      <email>ou-clinical-trials@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>J. S. Thompson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Oklahoma City</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>405-752-3402</phone>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Legacy Good Samaritan Hospital and Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Y. Kee</last_name>
      <phone>800-220-4937</phone>
      <email>cancer@lhs.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Y. Kee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin B. Bridges</last_name>
      <phone>503-215-2614</phone>
      <email>CanRsrchStudies@providence.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin B. Bridges</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delaware County Memorial Hospital</name>
      <address>
        <city>Drexel Hill</city>
        <state>Pennsylvania</state>
        <zip>19026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachelle M. Lanciano</last_name>
      <phone>610-284-8237</phone>
      <email>jolene.garney@crozer.org</email>
    </contact>
    <investigator>
      <last_name>Rachelle M. Lanciano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Pinnacle Cancer Center/Community Osteopathic Campus</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy F. Burns</last_name>
      <phone>717-724-6765</phone>
      <email>klitchfield@PINNACLEHEALTH.org</email>
    </contact>
    <investigator>
      <last_name>Timothy F. Burns</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NRG Oncology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Puneeth Iyengar</last_name>
      <phone>214-648-7097</phone>
      <email>puneeth.iyengar@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Puneeth Iyengar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Lu</last_name>
      <phone>215-955-6084</phone>
    </contact>
    <investigator>
      <last_name>Bo Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reading Hospital</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terrence P. Cescon</last_name>
      <phone>610-988-9323</phone>
    </contact>
    <investigator>
      <last_name>Terrence P. Cescon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Wyoming Valley/Henry Cancer Center</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiori Alite</last_name>
      <phone>570-271-5251</phone>
      <email>HemonCCTrials@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Fiori Alite</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lankenau Medical Center</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert S. DeNittis</last_name>
      <phone>484-476-2649</phone>
      <email>turzoe@mlhs.org</email>
    </contact>
    <investigator>
      <last_name>Albert S. DeNittis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Faris</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
      <email>kwilliams8@ghs.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Eastside</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
      <email>kwilliams8@ghs.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Self Regional Healthcare</name>
      <address>
        <city>Greenwood</city>
        <state>South Carolina</state>
        <zip>29646</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn D. Britten</last_name>
      <phone>864-725-4771</phone>
      <email>nmcgaha@selfregional.org</email>
    </contact>
    <investigator>
      <last_name>Carolyn D. Britten</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gibbs Cancer Center-Pelham</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia C. Griffin</last_name>
      <phone>864-560-6104</phone>
      <email>kmertz-rivera@gibbscc.org</email>
    </contact>
    <investigator>
      <last_name>Patricia C. Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Radiation Oncology Center-Hilton Head/Bluffton</name>
      <address>
        <city>Hilton Head Island</city>
        <state>South Carolina</state>
        <zip>29926</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard A. Zaren</last_name>
      <phone>912-819-5704</phone>
      <email>underberga@sjchs.org</email>
    </contact>
    <investigator>
      <last_name>Howard A. Zaren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Seneca</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <zip>29672</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
      <email>kwilliams8@ghs.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia C. Griffin</last_name>
      <phone>864-560-6104</phone>
      <email>kmertz-rivera@gibbscc.org</email>
    </contact>
    <investigator>
      <last_name>Patricia C. Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Spartanburg</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
      <email>kwilliams8@ghs.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center - Sioux Falls</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preston D. Steen</last_name>
      <phone>605-312-3320</phone>
      <email>OncologyClinicalTrialsSF@SanfordHealth.org</email>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Memorial Hospital and Cancer Center-Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond U. Osarogiagbon</last_name>
      <phone>901-226-3077</phone>
    </contact>
    <investigator>
      <last_name>Raymond U. Osarogiagbon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Puneeth Iyengar</last_name>
      <phone>214-648-7097</phone>
    </contact>
    <investigator>
      <last_name>Puneeth Iyengar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0565</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd A. Swanson</last_name>
      <phone>409-772-1950</phone>
      <email>clinical.research@utmb.edu</email>
    </contact>
    <investigator>
      <last_name>Todd A. Swanson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Gomez</last_name>
      <phone>713-792-3245</phone>
    </contact>
    <investigator>
      <last_name>Daniel Gomez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Li</last_name>
      <phone>210-450-3800</phone>
      <email>CTO@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Ying Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University Healthcare</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malcolm D. Mattes</last_name>
      <phone>304-293-7374</phone>
      <email>cancertrialsinfo@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Malcolm D. Mattes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora BayCare Medical Center</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54311</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen L. Ziaja</last_name>
      <phone>414-302-2304</phone>
      <email>ncorp@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Ellen L. Ziaja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gundersen Lutheran Medical Center</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Collin D. Driscoll</last_name>
      <phone>608-775-2385</phone>
      <email>cancerctr@gundersenhealth.org</email>
    </contact>
    <investigator>
      <last_name>Collin D. Driscoll</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander V. Louie</last_name>
      <phone>519-685-8600</phone>
    </contact>
    <investigator>
      <last_name>Alexander V. Louie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>April 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

